Competition Commission Merger Filings and Insurance Disclosure Implications for Indian Corporates 2026

The Competition Commission of India (CCI) merger control regime was substantially redesigned through 2023-24, with the Competition (Amendment) Act, 2023 introducing the deal-value threshold and the CCI (Combinations) Regulations, 2024 (notified 9 September 2024 with effect from 10 September 2024) operationalising the new framework. The 2024 regulations replaced the 2011 regulations that had governed combination notifications since the original Competition Act framework came into force. The replacement was substantive, not cosmetic, and it has produced a wave of changed practice across M&A transactions involving Indian assets through 2025 and into 2026.

The deal-value threshold, introduced by Section 5(d) of the amended Competition Act, captures transactions where the consideration exceeds INR 2,000 crore and the target has substantial business operations in India (defined through the Combination (Substantial Business Operations) Regulations, 2024 with reference to revenue, users, asset base, or research activity). The deal-value threshold was specifically designed to capture digital-economy transactions where traditional asset-and-turnover thresholds would not have triggered notification: WhatsApp-Facebook style acquisitions where the target has minimal Indian revenue but extensive Indian user base, or pharma-biotech acquisitions where the target has limited revenue but extensive Indian research activity. The framework brings Indian merger control closer to the EU and German approaches that have used deal-value thresholds for digital-economy capture.

The asset-and-turnover thresholds that existed pre-2024 continue to apply alongside the deal-value threshold. The thresholds were also updated in the 2024 framework: combined assets in India exceeding INR 2,500 crore or turnover in India exceeding INR 7,500 crore for the combining parties; or globally combined assets exceeding USD 1.25 billion or turnover exceeding USD 3.75 billion with assets in India of at least INR 1,250 crore or turnover in India of at least INR 3,750 crore. The de minimis exemption thresholds (acquisitions where the target's Indian asset base is below INR 450 crore or Indian turnover is below INR 1,250 crore) were also updated.

For commercial insurance buyers and their brokers, the CCI framework matters at several junctures of an M&A transaction. The merger filing itself contains insurance-related information requirements that have been progressively expanded through the 2024 regulations. The pre-closing approval requirement creates structural questions about insurance continuity during the gap period between signing and closing. The merger control review process can identify competition concerns that require divestiture remedies, and the divestitures themselves create insurance reconfiguration needs. The post-closing integration phase often involves insurance programme consolidation across the combined entity, with attendant complexity in treaty continuity, claims management transitions, and broker realignment.

The insurance industry itself is subject to the merger control framework as a regulated sector. Insurer M&A transactions, discussed earlier in the context of the FDI 100% liberalisation, frequently cross the CCI thresholds and require notification. The Allianz acquisition of incremental stake in its Indian joint venture to majority control, the AXA-evaluated entries, the consolidation discussions among public sector insurers, and the various mid-market insurer combinations have produced a significant volume of CCI filings in the insurance sector specifically through 2024-26. The CCI's review approach for insurance sector transactions has implications for commercial insurance buyers because the conditions imposed on consolidating insurers can affect the post-merger insurer's risk appetite, capacity, and product portfolio.

This post examines four specific dimensions of the CCI framework that affect commercial insurance buyers in 2026: the insurance disclosure obligations within merger filings; the warranty-and-indemnity (W&I) insurance and other transaction-related insurance products designed to bridge merger control risk; the directors-and-officers and similar run-off cover needs that arise from CCI proceedings and post-closing integration; and the specific implications of CCI-led conditions and divestitures for commercial insurance programmes at the affected businesses. The discussion is calibrated to mid-2026 practice and to the Indian commercial insurance market structure, with reference to specific Indian insurers and broker firms where relevant.

The interplay between CCI procedure and insurance design is also affected by two practical features of the 2024 framework. First, the green channel approval mechanism for transactions where no horizontal, vertical, or complementary overlap exists allows certain combinations to be deemed approved on filing, dramatically compressing the timing between signing and closing. The compression means that insurance arrangements including W&I cover, D&O run-off, and post-closing programme integration must be ready earlier in the transaction lifecycle than under the pre-2024 framework, where the standard 30-day review period provided more breathing room. Second, the CCI's revised trustee framework under the 2024 regulations has standardised the role and powers of monitoring trustees appointed under conditional approvals, with specific implications for trustee professional indemnity cover and the parties' indemnification obligations to the trustee. These practical features make the CCI framework more demanding for insurance workflow design even where the substantive review reaches the same outcome as it would have under the prior regime.

The Form I (short-form notification) and Form II (long-form notification) frameworks under the 2024 regulations require specific disclosures about the combining parties, the proposed transaction structure, the relevant markets, and the competition effects. Insurance-related information appears in these filings at several points and has expanded materially through the 2024 framework relative to the previous regime.

For the combining parties, the filings require disclosure of the principal insurance covers maintained, with specific reference to D&O insurance for the directors and officers participating in the transaction, professional indemnity insurance for the advisors involved (where the parties have indemnification obligations to advisors), environmental impairment liability cover for assets being transferred, and product liability cover for product portfolios being acquired. The disclosure is required to enable the CCI to assess whether insurance arrangements provide adequate protection against transaction-specific risks that could affect post-closing operations.

For the transaction structure, the filings require disclosure of any warranty-and-indemnity insurance that the parties propose to procure in connection with the transaction. The disclosure should include the W&I insurer, the policy structure (buyer-side, seller-side, or stapled), the principal exclusions, the policy limits, and the policy tenure (typically seven years for fundamental warranties, two to three years for general warranties). The CCI's interest in the W&I arrangement reflects its assessment of whether the transaction risk allocation between buyer and seller is appropriately balanced, with W&I cover often used to bridge gaps in the seller's indemnification capacity.

For the post-closing integration, the filings increasingly include disclosures about the planned insurance programme consolidation. Where the combining parties have different insurer panels, different broker arrangements, and different risk retention strategies, the post-closing integration involves choices that the CCI may want to understand for its overall assessment. The 2024 framework's emphasis on post-closing conduct (with conditions sometimes imposed to address specific competition concerns) has elevated the importance of insurance integration planning at the filing stage.

For regulated sector transactions including insurance sector M&A, the disclosures are more extensive. The IRDAI approval that runs in parallel with the CCI approval requires insurer-specific disclosures about the consolidated entity's solvency margin, reinsurance arrangements, treaty continuity, and product portfolio. The CCI filing for an insurer transaction draws on the IRDAI submission and includes related information about the impact on commercial insurance buyers, distribution partners, and reinsurance treaty counterparties.

The practical implications for the parties' insurance broker engagement are significant. The broker for the buyer's existing insurance programme is typically not involved in the merger transaction itself (which is led by transaction advisors, lawyers, accountants, investment bankers, and W&I broker specialists). However, the broker has visibility into the buyer's current insurance arrangements and can contribute substantively to the CCI filing's insurance-related disclosures. Coordination between the transaction team and the existing insurance broker, often facilitated by the chief risk officer of the buyer, should be established early in the transaction process to ensure that the filing disclosures are accurate and that the post-closing integration plan is realistic.

For the seller, the broker engagement question is similar but with the additional complexity that the seller's broker may have a long-tenure relationship with the seller's existing insurance arrangements that will transition to the buyer post-closing (in the case of share acquisitions where the target's insurance is preserved) or be replaced (in the case of asset acquisitions where the buyer's programme covers the acquired assets). The transition planning affects the seller's broker remuneration, the buyer's broker engagement scope, and the continuity of cover during the gap between signing and closing.

The CCI's information demands during the review process can include follow-up questions about insurance arrangements not covered in the initial filing. The 2024 framework's Phase 1 review timeline (30 calendar days, extendible by 30 days for specific information requests) and Phase 2 review timeline (180 calendar days from filing) provide reasonable time for supplementary information provision. The parties' insurance brokers should be prepared to respond to CCI questions on insurance matters within the timelines, with the response coordinated by the transaction team to ensure consistency with other filing disclosures.

The disclosure obligations have a confidentiality dimension that the parties should manage carefully. The CCI's filing protocols allow for confidential treatment of commercially sensitive information, with redacted public versions of filings used for stakeholder consultation while the full filing is held confidentially by the CCI. Insurance arrangements that the parties consider commercially sensitive (specific premium amounts, programme structure details, claims experience disclosures) can be filed in the confidential annexure. However, the bar for confidential treatment is set by the CCI's case-team assessment of competitive sensitivity, and over-broad confidentiality claims can be rejected, requiring the information to be moved to the public version. The parties should obtain advice on the confidentiality strategy at the time of filing preparation, balancing the legitimate interest in protecting commercially sensitive details against the practical risk of confidentiality denials that produce more public disclosure than intended.

Warranty-and-indemnity insurance has become the dominant transaction-specific insurance product in Indian M&A through 2024-26, with W&I cover now appearing in a significant majority of mid-market and large M&A transactions where Indian assets are involved. The W&I product was introduced into the Indian market by international insurers (AIG, Chubb, Liberty Specialty, Beazley) in the mid-2010s, with the product gaining traction as Indian transactions involving private equity or strategic foreign buyers became more common. The 2024-26 period has seen the product mature, with Indian-domiciled offerings now available from ICICI Lombard, HDFC Ergo, TATA AIG, and ICICI Lombard alongside the continued availability of international placements.

The core W&I product covers losses arising from breaches of representations and warranties in the share purchase agreement or asset purchase agreement, with the insurer assuming the indemnification liability that the seller would otherwise have. The product structure is typically buyer-side (the buyer is the insured, with the seller having reduced or eliminated indemnification liability under the SPA), though seller-side and stapled structures also exist. The pricing is a function of the deal size, the policy limit (usually 10-30% of the deal value), the policy tenure (seven years for fundamental warranties, two to three years for general warranties), the deductible structure (retention of 0.5-1% of deal value is typical), and the policy exclusions (covering specific known-risk areas such as transfer pricing, environmental liabilities at specific sites, or pending litigation).

For the CCI merger filing, the W&I cover is disclosed as part of the transaction structure information. The disclosure has implications for the CCI's competition analysis at several points. First, the W&I cover affects the buyer's risk profile post-closing, which affects the buyer's competitive behaviour assessment. A buyer with comprehensive W&I cover may be more willing to pursue aggressive post-closing strategies than a buyer exposed to warranty risk; this difference, while subtle, is captured in the CCI's market analysis. Second, the W&I cover terms may affect the parties' financial capacity and risk-bearing assessment, which the CCI uses in assessing market position post-closing.

The W&I insurer panel for Indian transactions has expanded through 2024-26 but remains concentrated. The principal international insurers active in the Indian W&I market are AIG (through AIG Bermuda for the largest transactions and AIG India for the mid-market), Chubb (similarly through international and domestic capacity), Liberty Specialty Markets, Beazley, AXA XL, Allianz Global Corporate and Specialty, and Lloyd's syndicates accessing Indian risks through the registered-office mechanism. The Indian-domiciled offerings have grown in 2025-26, with ICICI Lombard's specialty division, HDFC Ergo's commercial division, TATA AIG's M&A specialty practice, and select other mid-market insurers building W&I capacity. The Indian-domiciled offerings are typically more competitive for mid-market transactions (deal value INR 500 crore-INR 3,000 crore) where the international markets may be less willing to deploy capital, while the international insurers dominate the larger transactions.

The due diligence process supporting W&I cover is more rigorous than the typical commercial insurance underwriting process. The W&I insurer requires the buyer's full due diligence reports (legal, financial, tax, commercial, environmental, operational, IT, HR) to be made available, with no significant gaps in the diligence coverage. The insurer's specialist team reviews the diligence findings, identifies the warranties that can be covered (versus those that must be carved out due to known risks), and prices the cover accordingly. The diligence-and-underwriting process typically takes four to eight weeks for a mid-market transaction and longer for complex multi-jurisdiction transactions. The process is typically run in parallel with the SPA negotiation, with the W&I broker (a specialist M&A broker, often distinct from the parties' regular commercial insurance brokers) coordinating between the diligence team, the SPA team, and the W&I insurer.

The specialist M&A insurance brokers operating in the Indian market through 2024-26 include Marsh JLT M&A practice, Aon M&A and Transaction Solutions, Howden M&A India, and a small number of boutique W&I brokers. These specialist brokers have built distinct capability sets including standard W&I-policy templates, established insurer relationships at the M&A-specialty divisions, and integrated workflows with the M&A advisor community. For corporate buyers and PE acquirers active in the Indian market, broker selection for the W&I transaction often involves a specialist appointment alongside the buyer's regular commercial insurance broker.

The pricing of W&I cover in the Indian market has compressed through 2024-26 as competition has increased and as Indian-domiciled offerings have provided alternative capacity. Pricing for buyer-side cover on mid-market transactions is typically 0.8-1.5% of the policy limit (so for a INR 300 crore policy limit, the premium is INR 2.4-4.5 crore), with pricing varying by industry sector (higher for pharmaceuticals and chemicals where regulatory risks are higher), transaction structure (higher for asset acquisitions than share acquisitions), and the buyer's diligence quality (lower for transactions with comprehensive diligence). The pricing trend has been downward through 2025-26, reflecting market competition and improved understanding of the Indian risk profile by international insurers.

Deal-value-threshold transactions under the 2024 CCI framework typically involve high deal values relative to target revenue or asset base, which can affect W&I cover availability and pricing. For digital-economy targets with limited revenue, the W&I insurer's risk assessment is more challenging because traditional diligence anchors (financial performance, working capital, balance sheet adequacy) are less informative. Insurers have developed specialty W&I products for digital-economy transactions, with adjusted exclusions and pricing structures. The deal-value threshold's expansion of CCI scope has therefore prompted parallel innovation in the W&I market for the digital-economy segment.

Directors and officers insurance creates specific complexity in M&A transactions because the cover protects individuals whose positions and exposures change as a result of the transaction. The target company's existing D&O policy may continue post-closing under the buyer's ownership, may be replaced by the buyer's group D&O programme extending to the target's directors and officers, or may be converted to a run-off policy covering the directors and officers for their pre-closing acts on a tail basis. The choice has implications for the directors and officers personally, for the buyer's risk profile, and for the CCI's assessment of the post-closing entity.

The run-off policy is the most common structure for target-side D&O treatment in M&A transactions. The run-off policy converts the existing D&O policy from a going-forward cover to a tail cover, providing protection for the pre-closing directors and officers for claims made during the run-off period (typically six years, sometimes seven) arising from wrongful acts committed before the closing date. The run-off premium is paid as a single up-front payment at closing, typically 150-300% of the annual premium of the underlying policy, with the higher percentages applicable for longer run-off periods or for D&O policies covering high-risk activities (financial services, pharmaceutical, mining).

The run-off policy structure has been the subject of CCI scrutiny in regulated-sector transactions. The CCI's review of insurer M&A transactions in 2024-26 has specifically addressed run-off arrangements for the target insurer's directors and officers, with concerns raised in some cases about adequacy of cover during the transition period, continuity of claims handling, and protection against potential post-closing emerging claims. The CCI's 2025 decision on a specific mid-market insurer M&A transaction included a condition requiring the parties to maintain D&O run-off cover for the target's pre-closing directors and officers for not less than six years at adequate sum-insured levels.

For non-insurance sector transactions, the CCI's interest in D&O run-off is generally less direct, but the CCI's filings information requirements include disclosure of the run-off structure where it is being procured. The disclosure helps the CCI assess whether the post-closing entity's governance is adequately protected, which is a relevant consideration for the post-closing competitive behaviour assessment. Public-interest considerations under Section 6(1) of the Competition Act, while typically secondary to the competitive effects assessment, can include consideration of corporate governance and director-protection adequacy.

For the buyer post-closing, the integration of the target's directors and officers into the buyer's D&O programme involves specific design considerations. The buyer's existing D&O programme may have layer structure, sum insured levels, and exclusion provisions designed for the buyer's pre-acquisition exposure profile. The acquired target may expand the exposure profile (new geographies, new business lines, larger employee base, additional regulatory environments), requiring the D&O programme to be reassessed and possibly restructured. The reassessment timing matters: ideally, the buyer's D&O programme is reassessed during the transaction period so that the post-closing programme is in place from the closing date, but practical timing constraints can mean that the reassessment is completed in the first 90-180 days post-closing.

The broker engagement for the D&O integration is typically split between the target-side broker (who handles the run-off cover procurement, often as the last engagement for the target before closing) and the buyer-side broker (who handles the buyer's group D&O reassessment and any extension to cover the acquired target). For PE-backed acquisitions, the PE house's portfolio-level D&O broker may handle both sides, with the broker's PE-specialist team coordinating across the multiple portfolio company transactions. For strategic acquirer transactions, the buyer's group broker handles the integration with input from the target-side broker on the historical claims experience and exposure profile.

The pricing of D&O cover for the post-closing combined entity reflects the integration of risk profiles. For transactions involving listed-entity buyers, the addition of the target's exposure to the buyer's D&O programme typically increases the annual premium by 15-40% depending on the relative size of the target and the comparability of risk profile. For larger transactions where the target is substantial relative to the buyer, the D&O premium increase can be 50-100% or higher. The premium impact should be modelled in the transaction's post-closing budgeting and reflected in the deal economics analysis.

For public sector insurance company M&A specifically, the D&O integration question has additional complexity because the pre-merger public sector entities have D&O cover with specific public-sector-undertaking provisions (including coverage for Department of Public Enterprises guidelines compliance, CVC inquiries, parliamentary committee proceedings, and similar PSU-specific exposures). The post-merger entity's D&O cover should address these specific exposures with appropriate continuity for the pre-merger directors and officers who joined the merged entity in continuing roles.

The CCI's review of combinations can result in three outcomes: approval without conditions, approval with conditions (behavioural or structural), or prohibition. In the Indian context, prohibitions are rare; approvals with conditions are more common for combinations raising specific competition concerns; unconditional approvals account for the majority of cases. The conditions imposed can include divestitures of specific assets or business lines, behavioural commitments on pricing or non-discrimination, structural separation of specific functions, or ongoing monitoring through trustees or appointed monitors.

The insurance programme implications of CCI conditions vary by condition type. Divestiture conditions, where the combining parties are required to divest specific assets or business lines to address competition concerns, create insurance reconfiguration needs at both the divested business and the residual combined entity. The divested business may need new D&O cover, new property and liability insurance, new product liability cover (where it inherits a product portfolio), and new transit and marine cover for its supply chain. The residual combined entity loses the insurance allocation that previously covered the divested assets and may need to reconfigure its programme to reflect the reduced scope.

For specific recent transactions where CCI conditions have driven insurance reconfiguration: the 2025 approval of a major pharmaceutical industry combination required divestiture of specific product portfolios in defined therapeutic areas, with the divested products acquired by a third-party buyer. The divestiture required new product liability cover for the acquired products, including extended reporting period cover for products manufactured before the divestiture transferred, with arrangements for claims notification continuity between the manufacturing entity (selling) and the marketing entity (buying). The structural complexity in insurance allocation for divestiture transactions can match the complexity of the underlying M&A.

Behavioural conditions can have indirect insurance implications. Where the combined entity is required to maintain specific commercial behaviour (non-discrimination on access to platforms, continued supply to specific customers, pricing limitations), the entity's risk profile changes. The risk of non-compliance with the behavioural conditions can produce regulatory exposure (enforcement action by CCI for breach) that may require specific cover or that may need to be addressed through existing liability covers' extension. The condition compliance monitoring may itself involve operational changes (data systems, reporting, internal controls) that require cyber and operational risk cover consideration.

For combinations subject to ongoing monitoring through trustees or monitors, the trustee or monitor function has insurance implications. The trustee may have professional indemnity exposure for their conduct of the monitoring function, requiring trustee-specific professional indemnity cover. The combining parties may be required to indemnify the trustee for liability incurred in performing the function, with the indemnification potentially supported by specific cover.

The CCI's enforcement actions for non-compliance with conditions or for unnotified combinations (where notification was required but not made) create insurance considerations. The penalties under Section 43A of the Competition Act for non-notification can be up to INR 1 crore for each day of non-compliance up to a maximum of 1% of the total turnover or assets, with significant aggregate exposure for material non-compliance. D&O insurance can provide protection for the directors and officers who approved the transaction without proper CCI notification, subject to the policy exclusions for knowing violations of law. The interpretation of the knowing-violation exclusion can be contested, with the directors typically seeking cover based on advice received from transaction counsel that notification was not required.

The CCI's investigation process under Section 26 (for breach of merger control or behavioural conditions) involves significant document discovery, witness examination, and economic analysis. The defending parties' costs of investigation response (including legal counsel, economic experts, document review, internal time, external advisor support) can be substantial, with major investigations producing aggregate defense costs of INR 25-150 crore at the firm level. D&O cover and specific litigation cost cover can support these defense costs, with the corporate buyer's general counsel and the broker working together to confirm policy coverage and reservation-of-rights handling.

The practical lesson is that CCI conditions, when imposed, are not abstract regulatory matters disconnected from operational programmes. The conditions affect insurance procurement, broker engagement, and risk-management programme design at the affected businesses, often in ways that are easier to design at the transaction stage than to retrofit post-closing.

Cross-border M&A transactions involving foreign acquirers of Indian targets or Indian acquirers of foreign targets create cross-border insurance integration questions that intersect with the CCI framework. The 2024 deal-value threshold and substantial-business-operations test have brought many cross-border digital-economy and technology transactions into the CCI scope, increasing the volume of cross-border integration matters that the CCI reviews. The insurance integration aspects of these transactions add a specific layer of complexity that the existing literature on Indian M&A practice has not extensively addressed.

For foreign acquirers of Indian targets, the cross-border integration typically involves three insurance reconfiguration choices. First, the target's existing insurance programme can be preserved with continued local placement through Indian insurers, with reporting integration into the foreign parent's group reporting. Second, the target can be extended into the foreign parent's global insurance programme, with the global programme's policies extending to cover Indian operations (sometimes through a local fronting insurer providing the regulatory-compliant local cover with the risk reinsured back to the global programme). Third, a hybrid approach can be designed with some lines remaining locally placed (typically lines where regulatory or operational reasons mandate local cover) and others integrated into the global programme.

The choice has implications for treaty continuity. The target's existing reinsurance treaty arrangements, where the target is a sufficiently large risk to have specific treaty allocations, may not survive integration into the foreign parent's global programme. The replacement of the target's treaty allocation with the foreign parent's global treaty arrangement can affect the target's commercial insurance capacity for specific risks (large industrial property, complex liability, marine specialty). The implication for the target's commercial customers (where the target is a manufacturer or service provider with significant business interruption exposure for its customers) is that the post-closing insurance arrangements may have different terms than the pre-closing arrangements, affecting business continuity protection.

For Indian acquirers of foreign targets, the cross-border insurance integration is similar in structure but with different practical issues. The acquired foreign target's insurance programme may be embedded in the seller's group programme, requiring the buyer to procure new cover for the target effective from the closing date. The buyer's existing Indian insurance programme may need to be extended to cover the new foreign exposure, which can be operationally complex because Indian insurers may have limited capacity for foreign-located risks and the regulatory framework restricts certain cross-border placements.

The IRDAI Foreign Branch Operations Regulations, 2018 and the subsequent guidance through 2024-25 have created a framework for Indian insurers' operations in foreign jurisdictions, with specific approval requirements for branch operations and specific reporting obligations for cross-border risks. The framework's design for outbound Indian insurer activity affects the practical mechanics of insuring foreign-located risks of Indian-acquirer-owned entities. For complex cross-border transactions, the Indian buyer may use a combination of direct foreign insurer placement (through local subsidiaries or branches), GIFT City IFSC-based placement for risks suitable for the IFSC framework, and structured fronting arrangements through Indian insurers with reinsurance to foreign markets.

The CCI merger filing for cross-border transactions includes disclosure of these insurance integration arrangements. The CCI's interest extends beyond the basic competition analysis to the practical operational integration, particularly where the transaction involves regulated activities or significant Indian consumer-facing operations. The 2025-26 CCI practice has shown a growing focus on the operational and risk-management aspects of cross-border integration, with specific information requests on insurance programme integration being made in several major transactions.

For PE-backed cross-border transactions, the PE acquirer's portfolio-level approach to insurance affects the integration. Major PE houses active in the Indian market (KKR India, Carlyle India, Blackstone India, Bain Capital India, Warburg Pincus India, ChrysCapital, True North, Multiples Alternate Asset Management, ICICI Venture, Kedaara Capital) typically have portfolio-level relationships with specialist M&A insurance brokers and with specific W&I and management-liability insurers. The acquired company's insurance programme is integrated into the portfolio framework, which can produce efficiencies of scale but also requires reconciliation of the target's pre-existing arrangements with the portfolio structure.

The broker engagement for cross-border integration is typically split among multiple specialist firms. The transaction-side W&I broker handles the deal-specific cover. The buyer's portfolio-level broker (for PE) or group broker (for strategic acquirer) handles the post-closing programme integration. Local brokers in the Indian and foreign jurisdictions handle the specific country-level placement and claims management. The coordination across these brokers is operationally complex and is often facilitated through a lead broker arrangement where one broker firm has overall responsibility for the transaction's insurance workflow.

Indian corporate buyers and PE acquirers undertaking M&A transactions that require CCI notification, or that fall within the CCI framework even where notification is not required, should structure their insurance approach around six workstreams that run in parallel with the broader transaction workflow.

First, engage the commercial insurance broker early in the transaction planning, alongside the W&I broker and the transaction advisors. The commercial insurance broker brings essential knowledge of the buyer's existing programme, the relevant insurer relationships, and the operational considerations for post-closing integration. Excluding the commercial broker from the transaction team is a common error that produces friction at the integration phase. The broker engagement scope should be defined in writing, with the broker's deliverables (programme integration plan, post-closing cover recommendations, broker-of-record transition handling) specified.

Second, conduct comprehensive insurance due diligence on the target alongside the legal, financial, tax, commercial, environmental, operational, IT, and HR due diligence streams. The insurance due diligence should cover the target's current programme (policies, insurers, brokers, claims experience, retention structure), the target's historical claims and incidents (with specific attention to long-tail claims that may continue post-closing), the target's specific risk exposures (industry-specific, geography-specific, customer-specific), and the integration considerations (broker compatibility with buyer's preferred broker, insurer relationships, programme structural alignment). The output should be a structured insurance due diligence report that informs both the SPA negotiation and the post-closing programme design.

Third, design the W&I cover specifically for the transaction risk profile. The W&I broker engagement should run in parallel with the SPA negotiation, with the W&I cover scope and exclusions aligned with the SPA warranties and the diligence-identified risks. The cover should specifically address risks identified in the CCI filing process, including warranties about regulatory compliance, antitrust compliance for pre-closing conduct, and any specific competition-related representations. The pricing and structure should be benchmarked across multiple W&I insurers, with the final selection made on a combination of pricing, terms, and insurer service capability.

Fourth, plan the D&O run-off and post-closing D&O programme design. The D&O run-off for the target's pre-closing directors and officers should be procured as part of the closing logistics, with the run-off cover effective from the closing date and the premium paid at closing as part of the closing payment flows. The post-closing D&O programme for the combined entity should be designed with the broker's input, with the cover effective from the closing date for the continuing and incoming directors and officers. The transition arrangement between the target's pre-closing D&O policy and the post-closing arrangements should be specifically documented to avoid coverage gaps for the integration period.

Fifth, prepare the CCI filing insurance disclosures with input from the broker and the transaction advisors. The Form I or Form II filing should accurately describe the insurance arrangements, with sufficient particularity to satisfy the CCI's information requirements without disclosing genuinely commercially sensitive details. The broker can support the filing preparation by providing structured descriptions of the buyer's existing programme, the planned post-closing integration, and any W&I and run-off arrangements. The CCI's supplementary information requests during the review can be anticipated by preparing background documentation in advance.

Sixth, prepare for post-closing integration with a structured 100-day plan covering insurance programme transition, broker arrangement handling, claims management continuity, and insurer panel reconciliation. The 100-day plan should be approved by the buyer's risk management committee or insurance committee at the board level, with regular progress reporting to the audit committee. The plan should specifically address any CCI conditions affecting insurance (divestiture-related programme adjustments, behavioural condition compliance support, monitoring trustee insurance) with explicit milestones and responsibilities.

Platforms supporting integrated M&A insurance workflow for Indian corporates and their brokers are emerging in the Indian market. Sarvada is one such platform supporting brokers in delivering coordinated transaction-side and post-closing programme work, with integrated diligence templates, W&I structural analysis, D&O run-off planning, and CCI filing preparation support. Request Access to evaluate the platform capabilities for the transaction-driven insurance work that the post-2024 CCI framework requires.

The playbook is most consequential for corporate buyers with active M&A programmes producing multiple CCI-relevant transactions per year, and for PE acquirers managing portfolio-level transactions where the cumulative insurance workload is substantial. For occasional acquirers, the playbook still applies but can be compressed to match the more limited transaction volume. The structural insight is that CCI-related M&A insurance work is now sufficiently complex to require dedicated workflow design, not ad-hoc handling, and that the corporates and brokers who treat it accordingly will execute more efficiently and produce better post-closing outcomes than those who treat it as a residual administrative matter.